MedTrace Logo

A Study of Efficacy and Safety of AX-8 in Chronic Cough

NCT04866563 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2025-09-08

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, crossover, multicenter study of AX-8 in participants with unexplained or refractory chronic cough designed to evaluate the effectiveness of AX-8 in reducing cough frequency.

Conditions

  • Chronic Cough

Interventions

DRUG

AX-8, Part 1 of the study

orally disintegrating tablets, BID

DRUG

Placebo, Part 1 of the study

orally disintegrating tablets, BID

DRUG

AX-8, Part 2 of the study

orally disintegrating tablets, TID

DRUG

Placebo, Part 2 of the study

orally disintegrating tablets, TID

Sponsors & Collaborators

  • Axalbion SA

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Axalbion Therapeutics, LTD.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-11
Primary Completion
2025-06-16
Completion
2025-06-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04866563 on ClinicalTrials.gov